Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2021

Publisher Name :
Date: 19-Feb-2021
No. of pages: 138
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- 5-Alpha-Reductase Inhibitors

- Beta-Blockers

- Botanicals and Traditional Chinese Medicine

Segment by Application

- Hospital Pharmacies

- Retail Pharmacies

- Online Pharmacies

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Astellas Pharma

- Eli Lilly

- GlaxoSmithKline

- Sanofi

- ADC Therapeutics

- Bayer HealthCare

- Bristol-Myers Squibb

- Valeant Pharmaceuticals

- Endo Pharmaceuticals

- Foresee Pharmaceuticals

- Merck

- Novartis

- Advaxis

- Teva Pharmaceutical Industries

- Urologixs

- Agennix

- ANI Pharmaceuticals

- BHR Pharma

- Boehringer Ingelheim

- Sanpower Group

- Eisai

- Ferring

- IO THERAPEUTICS

- LIDDS

- Madrigal Pharmaceuticals

- Nymox Pharmaceutical

- Spectrum Pharmaceuticals

- Takeda Pharmaceuticals

Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2021

Table of Contents
1 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Medication
1.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3.1 Benign Prostatic Hyperplasia (BPH) Medication Sales Comparison by Application: (2021-2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue 2016-2027
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales 2016-2027
1.4.3 Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region: 2016 Versus 2021 Versus 2027
2 Benign Prostatic Hyperplasia (BPH) Medication Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2016-2021)
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites, Area Served, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Medication Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Region
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Analysis by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2016-2021)
4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2016-2021)
5 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Analysis by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2016-2021)
5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Astellas Pharma
6.1.1 Astellas Pharma Corporation Information
6.1.2 Astellas Pharma Description and Business Overview
6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Astellas Pharma Product Portfolio
6.1.5 Astellas Pharma Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Eli Lilly Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.3.4 GlaxoSmithKline Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 ADC Therapeutics
6.5.1 ADC Therapeutics Corporation Information
6.5.2 ADC Therapeutics Description and Business Overview
6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.5.4 ADC Therapeutics Product Portfolio
6.5.5 ADC Therapeutics Recent Developments/Updates
6.6 Bayer HealthCare
6.6.1 Bayer HealthCare Corporation Information
6.6.2 Bayer HealthCare Description and Business Overview
6.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Bayer HealthCare Product Portfolio
6.6.5 Bayer HealthCare Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bristol-Myers Squibb Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Valeant Pharmaceuticals
6.8.1 Valeant Pharmaceuticals Corporation Information
6.8.2 Valeant Pharmaceuticals Description and Business Overview
6.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Valeant Pharmaceuticals Product Portfolio
6.8.5 Valeant Pharmaceuticals Recent Developments/Updates
6.9 Endo Pharmaceuticals
6.9.1 Endo Pharmaceuticals Corporation Information
6.9.2 Endo Pharmaceuticals Description and Business Overview
6.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Endo Pharmaceuticals Product Portfolio
6.9.5 Endo Pharmaceuticals Recent Developments/Updates
6.10 Foresee Pharmaceuticals
6.10.1 Foresee Pharmaceuticals Corporation Information
6.10.2 Foresee Pharmaceuticals Description and Business Overview
6.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Foresee Pharmaceuticals Product Portfolio
6.10.5 Foresee Pharmaceuticals Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Merck Product Portfolio
6.11.5 Merck Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Corporation Information
6.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Novartis Product Portfolio
6.12.5 Novartis Recent Developments/Updates
6.13 Advaxis
6.13.1 Advaxis Corporation Information
6.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Advaxis Product Portfolio
6.13.5 Advaxis Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Teva Pharmaceutical Industries Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.15 Urologixs
6.15.1 Urologixs Corporation Information
6.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Urologixs Product Portfolio
6.15.5 Urologixs Recent Developments/Updates
6.16 Agennix
6.16.1 Agennix Corporation Information
6.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Agennix Product Portfolio
6.16.5 Agennix Recent Developments/Updates
6.17 ANI Pharmaceuticals
6.17.1 ANI Pharmaceuticals Corporation Information
6.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.17.4 ANI Pharmaceuticals Product Portfolio
6.17.5 ANI Pharmaceuticals Recent Developments/Updates
6.18 BHR Pharma
6.18.1 BHR Pharma Corporation Information
6.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.18.4 BHR Pharma Product Portfolio
6.18.5 BHR Pharma Recent Developments/Updates
6.19 Boehringer Ingelheim
6.19.1 Boehringer Ingelheim Corporation Information
6.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Boehringer Ingelheim Product Portfolio
6.19.5 Boehringer Ingelheim Recent Developments/Updates
6.20 Sanpower Group
6.20.1 Sanpower Group Corporation Information
6.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Sanpower Group Product Portfolio
6.20.5 Sanpower Group Recent Developments/Updates
6.21 Eisai
6.21.1 Eisai Corporation Information
6.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Eisai Product Portfolio
6.21.5 Eisai Recent Developments/Updates
6.22 Ferring
6.22.1 Ferring Corporation Information
6.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.22.4 Ferring Product Portfolio
6.22.5 Ferring Recent Developments/Updates
6.23 IO THERAPEUTICS
6.23.1 IO THERAPEUTICS Corporation Information
6.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.23.4 IO THERAPEUTICS Product Portfolio
6.23.5 IO THERAPEUTICS Recent Developments/Updates
6.24 LIDDS
6.24.1 LIDDS Corporation Information
6.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.24.4 LIDDS Product Portfolio
6.24.5 LIDDS Recent Developments/Updates
6.25 Madrigal Pharmaceuticals
6.25.1 Madrigal Pharmaceuticals Corporation Information
6.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.25.4 Madrigal Pharmaceuticals Product Portfolio
6.25.5 Madrigal Pharmaceuticals Recent Developments/Updates
6.26 Nymox Pharmaceutical
6.26.1 Nymox Pharmaceutical Corporation Information
6.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.26.4 Nymox Pharmaceutical Product Portfolio
6.26.5 Nymox Pharmaceutical Recent Developments/Updates
6.27 Spectrum Pharmaceuticals
6.27.1 Spectrum Pharmaceuticals Corporation Information
6.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.27.4 Spectrum Pharmaceuticals Product Portfolio
6.27.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.28 Takeda Pharmaceuticals
6.28.1 Takeda Pharmaceuticals Corporation Information
6.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
6.28.4 Takeda Pharmaceuticals Product Portfolio
6.28.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Cost Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
7.4 Benign Prostatic Hyperplasia (BPH) Medication Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors List
8.3 Benign Prostatic Hyperplasia (BPH) Medication Customers
9 Benign Prostatic Hyperplasia (BPH) Medication Market Dynamics
9.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Trends
9.2 Benign Prostatic Hyperplasia (BPH) Medication Growth Drivers
9.3 Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
9.4 Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
10 Global Market Forecast
10.1 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Type (2022-2027)
10.2 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Application (2022-2027)
10.3 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Medication by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Comparison by Application (2021-2027)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Covered in This Study
Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) of Key Manufacturers (2016-2021)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Manufacturers (2016-2021)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites and Area Served
Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2016-2021) & (KG)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2016-2021)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2016-2021) & (KG)
Table 19. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2016-2021)
Table 20. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2016-2021)
Table 22. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2016-2021) & (KG)
Table 23. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2016-2021)
Table 24. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2016-2021) & (KG)
Table 27. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2016-2021)
Table 30. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2016-2021) & (KG)
Table 31. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2016-2021)
Table 32. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2016-2021) & (KG)
Table 35. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2016-2021)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2016-2021)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million US$) by Type (2016-2021)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2016-2021)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2016-2021)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2016-2021)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (Million US$) by Application (2016-2021)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2016-2021)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2016-2021)
Table 48. Astellas Pharma Corporation Information
Table 49. Astellas Pharma Description and Business Overview
Table 50. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 51. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 52. Astellas Pharma Recent Developments/Updates
Table 53. Eli Lilly Corporation Information
Table 54. Eli Lilly Description and Business Overview
Table 55. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 56. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product
Table 57. Eli Lilly Recent Developments/Updates
Table 58. GlaxoSmithKline Corporation Information
Table 59. GlaxoSmithKline Description and Business Overview
Table 60. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 61. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product
Table 62. GlaxoSmithKline Recent Developments/Updates
Table 63. Sanofi Corporation Information
Table 64. Sanofi Description and Business Overview
Table 65. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 66. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product
Table 67. Sanofi Recent Developments/Updates
Table 68. ADC Therapeutics Corporation Information
Table 69. ADC Therapeutics Description and Business Overview
Table 70. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 71. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product
Table 72. ADC Therapeutics Recent Developments/Updates
Table 73. Bayer HealthCare Corporation Information
Table 74. Bayer HealthCare Description and Business Overview
Table 75. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 76. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product
Table 77. Bayer HealthCare Recent Developments/Updates
Table 78. Bristol-Myers Squibb Corporation Information
Table 79. Bristol-Myers Squibb Description and Business Overview
Table 80. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 81. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product
Table 82. Bristol-Myers Squibb Recent Developments/Updates
Table 83. Valeant Pharmaceuticals Corporation Information
Table 84. Valeant Pharmaceuticals Description and Business Overview
Table 85. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 86. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 87. Valeant Pharmaceuticals Recent Developments/Updates
Table 88. Endo Pharmaceuticals Corporation Information
Table 89. Endo Pharmaceuticals Description and Business Overview
Table 90. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 91. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 92. Endo Pharmaceuticals Recent Developments/Updates
Table 93. Foresee Pharmaceuticals Corporation Information
Table 94. Foresee Pharmaceuticals Description and Business Overview
Table 95. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 96. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 97. Foresee Pharmaceuticals Recent Developments/Updates
Table 98. Merck Corporation Information
Table 99. Merck Description and Business Overview
Table 100. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 101. Merck Benign Prostatic Hyperplasia (BPH) Medication Product
Table 102. Merck Recent Developments/Updates
Table 103. Novartis Corporation Information
Table 104. Novartis Description and Business Overview
Table 105. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 106. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 107. Novartis Recent Developments/Updates
Table 108. Advaxis Corporation Information
Table 109. Advaxis Description and Business Overview
Table 110. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 111. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 112. Advaxis Recent Developments/Updates
Table 113. Teva Pharmaceutical Industries Corporation Information
Table 114. Teva Pharmaceutical Industries Description and Business Overview
Table 115. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 116. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product
Table 117. Teva Pharmaceutical Industries Recent Developments/Updates
Table 118. Urologixs Corporation Information
Table 119. Urologixs Description and Business Overview
Table 120. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 121. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product
Table 122. Urologixs Recent Developments/Updates
Table 123. Agennix Corporation Information
Table 124. Agennix Description and Business Overview
Table 125. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 126. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product
Table 127. Agennix Recent Developments/Updates
Table 128. ANI Pharmaceuticals Corporation Information
Table 129. ANI Pharmaceuticals Description and Business Overview
Table 130. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 131. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 132. ANI Pharmaceuticals Recent Developments/Updates
Table 133. BHR Pharma Corporation Information
Table 134. BHR Pharma Description and Business Overview
Table 135. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 136. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 137. BHR Pharma Recent Developments/Updates
Table 138. Boehringer Ingelheim Corporation Information
Table 139. Boehringer Ingelheim Description and Business Overview
Table 140. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gross Margin (2016-2021)
Table 141. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product
Table 142. Boehringer Ingelheim Recent Developments/Updates
Table 143. Sanpower Group Corporation Information
Table 144. Sanpower Group Description and Business Overview
Table 145. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (Million US$), Price (USD/KG) and Gros
  • SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026
    Published: 01-Mar-2021        Price: US 4900 Onwards        Pages: 137
    This report provides a comprehensive overview of the size of the SARS-CoV-2 COVID Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials. Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021. However, our forecast indicates that an initial drop in 2022 will occur due to a number of factors including single booster shots as opposed to two sho......
  • 2020-2029 Report on Global Detox Product Market by Player, Region, Type, Application and Sales Channel
    Published: 28-Feb-2021        Price: US 2500 Onwards        Pages: 104
    The global Detox Product market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2020 and 2029. Since the COVID-19 virus outbreak in December 2019, the disease has spread to all countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect this industry in 202......
  • 2020-2029 Report on Global Post-operative Pain Management Market by Player, Region, Type, Application and Sales Channel
    Published: 28-Feb-2021        Price: US 2500 Onwards        Pages: 132
    The global Post-operative Pain Management market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2020 and 2029. Since the COVID-19 virus outbreak in December 2019, the disease has spread to all countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect thi......
  • (Post-pandemic Era) - Global Herbal Oil Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
    Published: 26-Feb-2021        Price: US 3650 Onwards        Pages: 118
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • Post-pandemic Era - Global Herbal Oil Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 26-Feb-2021        Price: US 3620 Onwards        Pages: 112
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Herbal Oil Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
    Published: 26-Feb-2021        Price: US 3160 Onwards        Pages: 97
    Summary At the time of this report, many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. It should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply chain, so it is inevitable to reconstruct the global industrial chain. Faced with the global industrial change in the post epidemic era, enterprises in var......
  • (Post-pandemic Era) - Global Excipients Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
    Published: 26-Feb-2021        Price: US 3650 Onwards        Pages: 105
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • Post-pandemic Era - Global Excipients Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 26-Feb-2021        Price: US 3620 Onwards        Pages: 105
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Excipients Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
    Published: 26-Feb-2021        Price: US 3160 Onwards        Pages: 81
    Summary At the time of this report, many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. It should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply chain, so it is inevitable to reconstruct the global industrial chain. Faced with the global industrial change in the post epidemic era, enterprises in var......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs